National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.

NCPE Assessment Process Complete
Rapid review commissioned 09/07/2018
Rapid review completed 27/07/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/08/2018
Pre-submission consultation with Applicant 03/09/2018
Submission received from Applicant 30/11/2018
Preliminary review sent to Applicant 26/03/2019
NCPE assessment re-commenced 25/04/2019
Factual accuracy check sent to Applicant 10/09/2019
NCPE assessment re-commenced 17/09/2019
NCPE assesssment completed 13/10/2019
NCPE assessment outcome The NCPE recommends that nivolumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*

Technical Summary Document

Plain English Summary

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.